Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (371-380 of 643) with videos related to

Pageof 65
Sort By:
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Advances in Therapy|March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Cancer Research|June 29, 2023
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast CancersJuliana Navarro-Yepes, Nicole M Kettner, Xiayu Rao, et al.
Plos One|December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implicationsChaitanya R Churi, Rachna Shroff, Ying Wang, et al.
JCO Precision Oncology|February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced CancersBenjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancer Research|November 3, 2017
"Personalized Cancer Therapy": A Publicly Available Precision Oncology ResourceKatherine C Kurnit, Ann M Bailey, Jia Zeng, et al.
Pageof 65

Showing results (371-380 of 643) with videos related to

Sort By:
Pageof 65
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Advances in Therapy|March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Cancer Research|June 29, 2023
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast CancersJuliana Navarro-Yepes, Nicole M Kettner, Xiayu Rao, et al.
Plos One|December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implicationsChaitanya R Churi, Rachna Shroff, Ying Wang, et al.
JCO Precision Oncology|February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced CancersBenjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancer Research|November 3, 2017
"Personalized Cancer Therapy": A Publicly Available Precision Oncology ResourceKatherine C Kurnit, Ann M Bailey, Jia Zeng, et al.
Pageof 65